Dysmenorrhea Market Report and Forecast 2024-2032

Dysmenorrhea Market Outlook

The dysmenorrhea market size is expected to grow at a CAGR of 5.7% during the forecast period of 2024-2032, driven by the rising incidence of endometriosis and uterine fibroids due to hormonal imbalances in women across major markets.

Dysmenorrhea Market Overview

Dysmenorrhea, also known as menstrual cramps, is a condition characterized by extreme pains in the lower abdomen. The pain may start 2-3 days prior to the onset of menstruation. The condition can be broadly categorized into primary and secondary dysmenorrhea. Secondary dysmenorrhea may be caused by other medical conditions like endometriosis, pelvic inflammatory disease, or uterine fibroids. Around 3.8% of young women with reproductive tract anomalies along with obstructive and non-obstructive anomalies may be related to secondary dysmenorrhea.

The rising dysmenorrhea market demand is directly impacted by the rising prevalence of conditions such as PCOS, adenomyosis, endometriosis or uterine fibroids. Dysmenorrhea affects approximately 16% to 91%  of the population in their reproductive age, with a high prevalence in adolescents (around 80%). Around 40% of adolescents are affected by severe dysmenorrhea. Severe pain is observed in 2-29% of individuals, and it impairs the quality of life of around 16-29% of the women. In addition, 12% of work and school activities may be affected due to absenteeism caused by dysmenorrhea.

Innovation in Existing Treatment Methods in the Dysmenorrhea Market

In December 2023, Dare Bioscience revealed a non-pharmacologic pain relief method for treating dysmenorrhea pain. DARE-PDM1  is a 1% diclofenac vaginal hydrogel being investigated to treat pain and was well-tolerated in the clinical assessment of 42 premenopausal women across various centers. This is the first-in-category product delivering diclofenac in a vaginal format which is expected to extend the duration of pain relief and reduce the risk of side effects associated with oral delivery of NSAIDs. The advent of the latest methods is projected to boost the dysmenorrhea market share in the forecast period as well.

Focus on Alternative Methods to Address a Wider Section of Patients

In November 2023, an Ayurvedic cannabis startup called HempStreet  raised USD 1 million in pre-Series A funding aimed at expanding its activities delivering effective menstrual cramps and pain treatment segment by facilitating expediated research and development and clinical trials for developing ayurveda-inspired products. Such initiatives are expected to bolster the dysmenorrhea market growth across the world.

Development in Surgical Procedures to Offer Alternatives to Pharmacological Interventions

Along with pharmacological interventions, surgical procedures are also used for patients with persistent and prolonged menstrual pain. Transcutaneous electrical nerve stimulation, empiric GnRH analog therapy is generally used as a second-tier treatment intervention with nonhormonal and/or hormonal therapies.

The rising advances in medical and healthcare technologies further fuel the dysmenorrhea market value. In severe cases, endometrial ablation and hysterectomy are also used. In July 2023, a new hysterectomy procedure called Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES ), that leaves no scars and causes minimal pain was performed at an Australian hospital for the first time. It offers a better approach to the fallopian tubes and ovaries and helps with reduced recovery time when compared to standard procedures.

In addition, other supportive therapies such as behavioral counselling, physiotherapy treatments and alternative medicines such as acupressure along with proper nutrition are also prescribed by healthcare professionals. This indicates the rising adoption naturopathy to treat dysmenorrhea.

Adoption of Combination Treatment is a Vital Dysmenorrhea Market Trend

The first-tier treatment for dysmenorrhea includes medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen (paracetamol), and hormonal contraception. However, to offer improved treatment solutions to patients, combination therapies are employed in patients. Estrogen-progestin pills such as oral pills, transdermal patches and vaginal rings are some of the commonly used treatment alternatives. Progestin only options are also available which constitute injections and levonorgestrel (LNG) releasing intrauterine devices among others. In a July 2023 study conducted by Cochrane researchers, revealed that combined oral contraceptive pills  may be the upcoming treatment alternative as it has displayed promising results in treating dysmenorrhea well.

Dysmenorrhea Market Segmentation

Market Breakup by Treatment Type

• Non-steroidal Anti-inflammatory Drugs (NSAIDs)

• Hormonal Therapy

Market Breakup by Disease Type

• Primary Dysmenorrhea

• Secondary Dysmenorrhea

Market Breakup by End User

• Hospitals

• Homecare

• Specialty Clinics

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Dysmenorrhea Market Regional Analysis

North America, particularly United States and Canada, is anticipated to lead the dysmenorrhea market share in the forecast period. The high prevalence of the condition in the region is a major aspect of the market size as women leading a sedentary lifestyle and following unhealthy dietary habits are more susceptible to develop the condition. In addition, the well-structured medical ecosystem facilitates easy availability of over the counter (OTC) pain relief medications, which further fuels the market share.

In Europe, there is a typically higher awareness of women’s health issues along with a well-developed healthcare infrastructure. Hence, it is a major player in the market. The market is currently witnessing a mix of both pharmaceutical as well as naturopathy therapies, as the population is inclining towards holistic homecare remedies for treating dysmenorrhea. Such cultural shifts will impact on the market value significantly in the forecast period.

The Asia Pacific dysmenorrhea market growth is driven by the increasing prevalence of traditional medicine and herbal remedies to treat the condition. With a substantial part of the population suffering from dysmenorrhea, several non-profit organizations and prominent healthcare companies are setting up essential awareness campaigns to educate the rural community about the disease. Alternatively, there have been significant efforts to improve the healthcare infrastructure as well.

Dysmenorrhea Market: Competitor Landscape

In October 2023, Mithra Biotech , a company dedicated to women’s health received approximately USD 3 million investment from Fuji Pharma. With the investment, Mithra envisions at redefining fem health by delivering innovative products in the domain of menopause as well as contraception. This also indicates the rising trend of growth in fundings to expand product portfolios.

The key features of the dysmenorrhea market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Novartis AG

• Bayer AG

• Abbott Laboratories

• F. Hoffmann-La Roche Ltd

• Sanofi

• Pfizer Inc.

• GlaxoSmithKline PLC

• Focus Consumer Healthcare

• Johnson & Johnson

• Alvogen

• Amgen Inc.

• Boehringer Ingelheim International GmbH.

• Ipsen Pharm

• Spectrum Pharmaceuticals, Inc.

• Takeda Pharmaceutical Company Limited

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Dysmenorrhea Market Report Snapshots

Dysmenorrhea Market Size

Dysmenorrhea Market Regional Analysis

Dysmenorrhea Treatment Companies